Condition: ST Elevated Myocardial Infarction · Sponsor: Assistance Publique - Hôpitaux de Paris
The main objective is to compare the effect of a single injection of two doses of rituximab versus placebo on 6 months left ventricular systolic function, using CMR, in patients who have had an acute anterior STEMI. Following the sponsor's decision to stop enrolment in the 200 mg arm, the primary objective of the study is to evaluate the efficacy of a single 1000 mg dose of rituximab versus placebo. The primary endpoint is the left ventricular ejection fraction (LVEF) by CMR at 6 months.
This description comes directly from the study's public registry record.
Gabriel STEG · 01 40 25 86 68 · gabriel.steg@aphp.fr
Ziad MALLAT · 01 53 98 80 06 · ziad.mallat@inserm.fr
Always discuss trial participation with your own doctor first.
| Cardiology department, Hôpital Bichat, AP-HP | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05211401